ADK-709 — Expedition Endurance Journal, a Panacea Bio Chem monograph by Bogdan Dicoias Panacea Bio Chem · Expedition Endurance Journal · Updated Sep 2026

Basecamp › How It Works

Chapter II · Mechanism

How It Works — dopamine at the source, not at the synapse

Classic stimulants squeeze more signal out of the dopamine you already have. Bromantane does something stranger and more elegant: it tells the cell to make more of the machinery that makes dopamine. The rate-limiting enzyme of that machinery is tyrosine hydroxylase (TH) — and turning its gene up is the best-documented thing bromantane does.

The dopamine synthesis pathway — tyrosine to L-DOPA to dopamine — with bromantane upregulating the tyrosine hydroxylase and DOPA-decarboxylase steps L-tyrosine L-DOPA dopamine tyrosine hydroxylase (TH) ↑ DOPA-decarboxylase (DDC) ↑ rate-limiting step bromantane upregulates TH and DDC gene expression — the cell builds more of its own production line gene expression → enzyme protein → L-DOPA → dopamine: de novo synthesis, not forced release
Fig. 3 — the synthesis line bromantane feeds. TH converts tyrosine to L-DOPA; DDC converts L-DOPA to dopamine. Bromantane raises the expression of both genes. Scientific illustration — not experimental imagery.

§01The core finding — gene expression first

In the landmark 2004 study (Vakhitova, Iamidanov, Seredenin — the Seredenin laboratory being one of bromantane's birthplaces), a single oral dose of ladasten in rats induced expression of the tyrosine hydroxylase and DOPA-decarboxylase genes in the striatum and hypothalamus. L-DOPA and dopamine then accumulated in step with that transcriptional activation — the signature of de novo synthesis, not of release or reuptake blockade.

A 2007 follow-up in Neuropharmacology confirmed and extended the picture: TH was upregulated — both messenger RNA and protein — alongside dopamine and L-DOPA across the ventral tegmental area, nucleus accumbens, hypothalamus, striatum and hippocampus. The same team reported that bromantane transformed hippocampal short-term potentiation into a protein-synthesis-dependent, D1/D5-receptor-dependent long-term potentiation — blocked by anisomycin and by SCH23390 — tying the gene-expression mechanism to a plasticity readout.

An epigenetic correlate has also been reported: cytosine demethylation in the TH gene promoter in rat hypothalamus (a single-source finding from the Russian literature — filed here as such).

§02What it is not

Not a classic releaser

Microdialysis does show increased striatal dopamine release and metabolism — but through newly synthesised transmitter, in the pattern expected from TH upregulation rather than the massive efflux of an amphetamine.

Not a meaningful reuptake inhibitor

In-vitro monoamine reuptake inhibition requires 50–500 µM — concentrations far above anything clinically relevant. Reuptake blockade is not the mechanism.

Not exhausting

Actoprotectors are defined by non-exhaustive action: the effect arrives without hyperstimulation and leaves without a crash — the clinical mirror of a synthesis-side mechanism.

§03The supporting cast — GABA, immune, neurotrophins

GABA-ergic component. The actoprotector review describes strengthened GABA-ergic mediation and reduced GABA-transporter expression — the proposed basis of bromantane's unusual anxiolytic-without-sedation profile. The source is a secondary review of Russian literature, so this journal files it at review tier.

Immunomodulation. In animal work: increased B-cell levels and circulating immune complexes even after a single dose; normalisation of T-cell subpopulations and the CD4/CD8 ratio in chronically stressed mice; and lowered pro-inflammatory cytokines (IL-6, IL-17) in an anxious-depression mouse model. No human immune-outcome trials exist yet.

Neurotrophins. Increased BDNF and NGF expression with MAP-kinase activation has been reported (a real, traceable citation — but a single source, so treated accordingly).

§04The honest gaps

What remains unknown

The exact molecular trigger — the receptor or target upstream of TH gene expression — remains unknown. Protein kinase A and C activation are implicated, and hypotheses about sigma-1 receptors circulate for adamantanes generally, but none has been demonstrated for bromantane itself. Nearly all mechanistic data are Russian and preclinical; human mechanistic studies are the open frontier — one reason the Panacea programme treats this compound as an investigation, not a settled file.

Raise the enzyme, and the cell makes more of its own transmitter on its own schedule. That is a fundamentally gentler way to buy endurance — and a much harder thing to engineer than a whip.

§05Where this leads

Mechanism becomes benefit in The Benefits, Mapped; the people who discovered all of this are credited in From Soviet Laboratories; and common mechanism questions are answered in Field Notes & FAQ.

§06Trending at basecamp

§07References for this chapter

  1. Vakhitova IuV, Iamidanov RS, Seredinin SB. Ladasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brain. Eksp Klin Farmakol. 2004;67(4):7-11. PMID 15500036
  2. Mikhaylova M, Vakhitova JV, Yamidanov RS, et al. The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats. Neuropharmacology. 2007;53(5):601-8. PMID 17854844 · doi:10.1016/j.neuropharm.2007.07.001
  3. Grekhova TV, et al. Effect of bromantane on the dopaminergic system of the rat brain. Biull Eksp Biol Med. 1995;119(3):302-4. PMID 7795203
  4. Tallerova AV, et al. Immunomodulatory activity of bromantane in chronically stressed mice. Bull Exp Biol Med. 2014;156(3):335-7. PMID 24771370 · doi:10.1007/s10517-014-2343-1
  5. Oliynyk S, Oh S. The pharmacology of actoprotectors. Biomol Ther (Seoul). 2012;20(5):446-56. PMC3762282